Drug Database
IV

IVIG (BT 681 5% / IVIG 5%, Biotest / IVIG 10%, Biotest)

✓ Approved

Grifols, S.A. · 单克隆抗体 · 单克隆抗体

什么是 IVIG?

IVIG 是一种单克隆抗体,由Grifols, S.A.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名BT 681 5%, IVIG 5%, Biotest, IVIG 10%, Biotest
公司Grifols, S.A.
药物类别单克隆抗体, 多克隆抗体, 抗体
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

IVIG 针对 8 个适应症,涉及 5 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersChronic inflammatory demyelinating polyradiculoneuropathy✓ Approved
Immune system disordersSelective IgG subclass deficiency✓ Approved
Nervous system disordersMultifocal motor neuropathy✓ Approved
Nervous system disordersGuillain-Barre syndrome✓ Approved
Blood and lymphatic system disordersThrombocytopenia✓ Approved

注册免费账户还可查看另外 3 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedBMC neurology2026-11-17

Clinical and treatment profiles of myasthenic crisis patients in a tertiary hospital in the Philippines: a single-center retrospective study.

Guinal Safrollah M SM, Tabuzo Mykha Marie B MMB, Turalde Christian Wilson R CWR

Myasthenic crisis is a life-threatening complication of myasthenia gravis. Data on its clinical profile and outcomes in resource-limited settings are limited. A retrospective review of pediatric and adult myasthenic crisis patients admitted at Philippine General Hospital from 2015 to 2024 was conducted. Sociodemographic, clinical, treatment, and outcome data were extracted from inpatient charts. Descriptive statistics and Pearson's chi-square, Fisher's exact, Wilcoxon rank-sum, and Kruskal-Wallis tests were used to analyze associations between clinical characteristics and outcomes. Eighty-two patients were included, mostly female (n = 49, 59.8%) with peak onset in the third decade. Infection was the leading precipitant of crisis, while hypertension, diabetes, and tuberculosis were common comorbidities. Nearly all required ventilation (96.3%, median nine days). Mortality was 13.4% (n = 11), mainly due to sepsis and respiratory failure. Younger age (< 30 years, p = 0.021) was linked to improved survival, whereas absence of intravenous immunoglobulin (IVIG) or therapeutic plasma exchange (TPE) was associated with higher mortality (p = 0.012). This study provided one of the largest descriptions of myasthenic crisis in the Philippines, demonstrating that infection remains the predominant inciting factor and timely rescue immunotherapy is associated with improved survival. These findings support strengthening access to specialized neuromuscular care and crisis-directed therapies in resource-constrained settings.

PMID 43040480
阅读全文 →
PubMedJournal of hematology2026-11-17

Measles Pneumonia After Allogeneic Hematopoietic Stem Cell Transplantation.

Jimenez-Ochoa Marco Alejandro MA, Contreras-Serratos Maria Margarita MM, Urbina-Escalante Elizabeth E, Pardo-Escobedo Maria Gabriela MG et al.

Measles is a highly contagious viral infection that is rarely reported after allogeneic hematopoietic stem cell transplantation (HSCT), with only a limited number of cases described in the literature. We report the case of a 46-year-old woman who developed laboratory-confirmed measles complicated by atypical pneumonia 3 years after human leukocyte antigen (HLA)-identical sibling allogeneic HSCT for acute lymphoblastic leukemia. Her post-transplant course had been complicated by steroid-refractory chronic graft-versus-host disease (GVHD), successfully treated with ruxolitinib, which had been discontinued only a few months before presentation. She was admitted with fever, severe odynophagia, and diffuse oral mucosal erythema, leading to an initial diagnosis of chronic GVHD flare and treatment with corticosteroids and empirical antimicrobials. During hospitalization, she rapidly developed hypoxemic respiratory failure and a characteristic cephalocaudal maculopapular rash. Reverse transcription polymerase chain reaction (RT-PCR) of a throat swab confirmed measles virus infection. Corticosteroids were discontinued, and the patient received supportive care and intravenous immunoglobulin (IVIG), with complete clinical and radiologic recovery. Notably, despite adequate quantitative immune reconstitution, including preserved CD4+ and CD8+ T-cell counts and normal immunoglobulin levels, she remained susceptible to measles because she was not yet eligible for measles-mumps-rubella (MMR) vaccination according to current post-transplant recommendations. This case highlights the diagnostic challenge of distinguishing measles from chronic GVHD in transplant recipients, emphasizes that quantitative immune recovery does not necessarily reflect pathogen-specific immunity, and underscores the importance of maintaining a high index of suspicion and performing early molecular testing during community outbreaks.

PMID 43042413
阅读全文 →
PubMedRinsho shinkeigaku = Clinical neurology2026-11-16

[A case of immune-mediated necrotizing myopathy complicated with immune thrombocytopenia successfully treated with intravenous immunoglobulin].

Kubo Hitoshi H, Yoshida Akira A, Ohtsubo Haruki H, Shiraoka Akira A et al.

A 41-year-old woman diagnosed with polymyositis had been treated with tacrolimus and repeated an intravenous immunoglobulin (IVIg) over past 14 years, due to worsening symptoms. Preadmission examinations showed thrombocytopenia. We diagnosed with immune thrombocytopenia (ITP) based on positive anti-platelet antibody and increased megakaryocytes on bone marrow examination. Following IVIg, both her muscle weakness and platelet counts normalized. The unique clinical course of this case prompted a reconsideration of her underlying muscular disease. Myopathological reexamination revealed predominantly necrotic and regenerating muscle fibers, and the presence of anti-HMGCR antibodies led to a revised diagnosis of immune-mediated necrotizing myopathy (IMNM) with ITP. Idiopathic inflammatory myopathy combined with ITP has been rarely reported. However, there are no prior reports of IMNM complicated with ITP. If thrombocytopenia is documented during the course of treatment in patients with IMNM, the complication of ITP should be taken into account when formulating the treatment strategy.

PMID 43035911
阅读全文 →
PubMedBMC pediatrics2026-11-16

A machine-learning-derived online prediction model for coronary artery aneurysm risk in children with kawasaki disease: a retrospective cohort study.

Ma Yiwen Y, Sun Yueyi Y, Zhang Hui H, Zhou Jinhui J et al.

Coronary artery aneurysm (CAA) is the most serious complication of Kawasaki disease (KD) and is associated with long-term cardiovascular morbidity. Early identification of children at high risk of CAA remains challenging. We aimed to develop and temporally validate a machine learning-based prediction model for individualized CAA risk assessment in children with KD. In this retrospective cohort study, 1,930 children diagnosed with KD at The Second Affiliated Hospital of Wenzhou Medical University between January 2018 and March 2025 were included. Among them, 1,378 patients diagnosed between January 2018 and December 2023 constituted the development cohort and were randomly divided into a training set and an internal test set. A further 552 patients diagnosed between January 2024 and March 2025 were used as an independent temporal validation cohort. Forty-two demographic, clinical, laboratory, and composite biomarker variables were initially considered. Least Absolute Shrinkage and Selection Operator (LASSO) regression was used for feature selection after preprocessing. Ten machine-learning algorithms were developed and compared. The model was designed to be applied after the initial IVIG response had been determined. Model performance was evaluated using discrimination, calibration, and decision curve analysis. Model interpretability was assessed using Shapley Additive Explanations (SHAP). 12 predictors were retained in the final model, including age, intravenous immunoglobulin (IVIG) resistance, IVIG administration time, oral mucosal changes, albumin, hematocrit, platelet count, prothrombin time, D-dimer, NT-proBNP, prognostic nutritional index, and C-reactive protein-to-albumin ratio. Among the ten algorithms, the Random Forest model showed the best overall performance, achieving an area under the receiver operating characteristic curve (AUC) of 0.899 (95% CI, 0.870-0.928) in the internal test set and 0.847 (95% CI, 0.812-0.882) in the temporal validation cohort. Calibration and decision curve analyses indicated good agreement and clinical utility. We developed and temporally validated a machine-learning model for predicting CAA risk in children with KD. The model has been deployed as an online tool to support early risk stratification. Further prospective multicenter validation is needed before routine clinical implementation.

PMID 43035742
阅读全文 →
PubMedFrontiers in pediatrics2026-11-15

Ruxolitinib in IVIG-resistant kawasaki disease-associated macrophage activation syndrome complicated by a giant coronary artery aneurysm: a case report and narrative literature review.

Zhang Fan F, Li Xuan X, Chen Ye Y, Wang Bo B et al.

Kawasaki disease (KD)-associated macrophage activation syndrome (KD-MAS) is a life-threatening complication with limited treatment options. Ruxolitinib, a JAK1/2 inhibitor, has shown efficacy in refractory systemic juvenile idiopathic arthritis-associated MAS (sJIA-MAS) and hemophagocytic lymphohistiocytosis (HLH). Its use in KD-MAS has been described in one previous case treated with ruxolitinib plus corticosteroids; use in a patient who also developed a giant coronary artery aneurysm has not been reported. A 3-month-old male infant with IVIG-resistant KD developed persistent fever despite two courses of IVIG, the first given before referral, and methylprednisolone pulse therapy. KD-MAS was diagnosed on the basis of bicytopenia, hyperferritinemia, elevated soluble CD25, hypofibrinogenemia, and hemophagocytes in the bone marrow. Ruxolitinib was initiated early. Body temperature normalized within 72 h, with rapid improvement in inflammatory markers. Coronary dilation was documented on illness day 22. By illness day 24, the left anterior descending artery (LAD) met giant-aneurysm criteria (Z-score: 10.93; later peak 11.9), whereas the proximal right coronary artery remained a medium aneurysm (peak Z-score: 5.73). After a third course of IVIG and long-term antithrombotic therapy with aspirin plus low-molecular-weight heparin, the aneurysms regressed over 16 months of follow-up. Clinical and laboratory improvement temporally followed the addition of ruxolitinib, although the contribution of ruxolitinib cannot be separated from concomitant IVIG and glucocorticoid therapy. A narrative literature review identified ten relevant studies. Reported KD-MAS treatment is predominantly IVIG plus glucocorticoids, with cyclosporine A and biologics reserved for refractory cases. This case is the second published report of ruxolitinib in KD-MAS, and the first to document a giant coronary artery aneurysm with 16-month coronary follow-up. KD-MAS should be suspected in IVIG-resistant KD with persistent fever and cytopenias. Addition of ruxolitinib was temporally associated with rapid clinical and inflammatory-marker improvement; however, its independent therapeutic contribution cannot be determined because of concurrent IVIG and glucocorticoid therapy. Systemic inflammatory improvement did not prevent coronary progression, so intensive coronary surveillance must continue.

PMID 43031993
阅读全文 →
PubMedCureus2026-11-15

Safety of Hormonal Contraceptives in Patients With Common Variable Immunodeficiency (CVID) Receiving Immunoglobulin Replacement: Evaluating the Risk of Thromboembolism.

Anderson Lorraine L, Tsai Monica M, Thakor Philipp Ami A

This case report discusses the use of hormonal contraceptives in patients with common variable immunodeficiency (CVID) who are on immunoglobulin replacement therapy (IgRT) and the risks of thromboembolism. We present a case of a 32-year-old female with CVID on weekly subcutaneous immunoglobulin (SCIG) who required consultation regarding thromboembolism risk prior to initiation of hormonal contraception for the treatment of dysmenorrhea and endometriosis. In this case, we explore the thromboembolic risks of IgRT and hormonal contraceptives, as well as considerations for an immunodeficient patient on replacement-dose immunoglobulin supplementation with gynecological conditions. While there are no clear guidelines on this issue, treatment considerations involve selection of the appropriate hormonal contraceptive, the appropriate route of contraceptive delivery, and recognition that SCIG replacement has fewer systemic adverse events than intravenous immunoglobulin (IVIG) replacement.

PMID 43032841
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多IVIG